Back to Search Start Over

Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.

Authors :
Pergolizzi JV Jr
Dahan A
Ann LeQuang J
Raffa RB
Source :
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Dec; Vol. 46 (6), pp. 1501-1504. Date of Electronic Publication: 2021 Jun 10.
Publication Year :
2021

Abstract

What Is Known and Objective: Food and Drug Administration (FDA) risk evaluation and mitigation strategies (REMs) encourage emergency responders, paramedics, law enforcement agents, and even laypeople to be trained in the administration of naloxone with the intent of rescuing individuals from a known or suspected opioid overdose.<br />Comment: Although naloxone is generally safe and effective at reversing respiratory depression caused by a conventional opioid such as morphine or heroin by competing with the opioid and displacing it from the μ-opioid receptor, questions increasingly are arising as to whether naloxone can adequately reverse opioid overdoses that may involve the potent opioids fentanyl and its analogues (F/FAs). In other words, as more and more opioid overdoses involve F/FAs, can naloxone keep up?<br />What Is New and Conclusion: As a competitive antagonist at μ-opioid receptors, naloxone is often a life-saving agent in cases of overdose caused by conventional opioids, but it may not be versatile or powerful enough to combat the rising tide of overdoses due to fentanyl and its illicit analogues, or in cases of overdose involving combinations of opioids and non-opioids.<br /> (© 2021 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2710
Volume :
46
Issue :
6
Database :
MEDLINE
Journal :
Journal of clinical pharmacy and therapeutics
Publication Type :
Academic Journal
Accession number :
34111307
Full Text :
https://doi.org/10.1111/jcpt.13462